{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:31:11Z","timestamp":1778589071015,"version":"3.51.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T00:00:00Z","timestamp":1539993600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Novartis Oncology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00277-018-3526-z","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:57:12Z","timestamp":1540033032000},"page":"241-253","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treating early-stage myelofibrosis"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sabattini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Maffioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,20]]},"reference":[{"key":"3526_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"3526_CR2","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F (2014) How I treat myelofibrosis. Blood 124:2635\u20132642. https:\/\/doi.org\/10.1182\/blood-2014-07-575373","journal-title":"Blood"},{"key":"3526_CR3","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113:2895\u20132901. https:\/\/doi.org\/10.1182\/blood-2008-07-170449","journal-title":"Blood"},{"key":"3526_CR4","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","volume":"116","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, Tefferi A (2010) Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 116:2857\u20132858. https:\/\/doi.org\/10.1182\/blood-2010-06-293415","journal-title":"Blood"},{"key":"3526_CR5","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","volume":"29","author":"N Gangat","year":"2011","unstructured":"Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29:392\u2013397. https:\/\/doi.org\/10.1200\/JCO.2010.32.2446","journal-title":"J Clin Oncol"},{"key":"3526_CR6","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Guglielmelli P, Rotunno G et al (2014) Mutation-Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. Blood 124:abstract 405","DOI":"10.1182\/blood.V124.21.405.405"},{"key":"3526_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"35","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G et al (2018) MIPSS70: Mutation-Enhanced International Prognostic Score System for transplantation-age patients with primary myelofibrosis. J Clin Oncol 35:310\u2013318. https:\/\/doi.org\/10.1200\/JCO.2017.76.4886","journal-title":"J Clin Oncol"},{"key":"3526_CR8","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1038\/leu.2017.169","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, de Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM (2017) A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia 31:2726\u20132731. https:\/\/doi.org\/10.1038\/leu.2017.169","journal-title":"Leukemia"},{"key":"3526_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","volume":"27","author":"G Barosi","year":"2014","unstructured":"Barosi G (2014) Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol 27:129\u2013140. https:\/\/doi.org\/10.1016\/j.beha.2014.07.004","journal-title":"Best Pract Res Clin Haematol"},{"key":"3526_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.humpath.2013.08.021","volume":"45","author":"X Gong","year":"2014","unstructured":"Gong X, Lu X, Xiao X, Wang W, Yang J, Fu Y, Zheng Y, Tang Q, Zhang X (2014) Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients. Hum Pathol 45:498\u2013503. https:\/\/doi.org\/10.1016\/j.humpath.2013.08.021","journal-title":"Hum Pathol"},{"key":"3526_CR11","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","volume":"28","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Silver RT, Barel A, Orazi A (2015) Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol 28:1315\u20131323. https:\/\/doi.org\/10.1038\/modpathol.2015.93","journal-title":"Mod Pathol"},{"key":"3526_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/IJGM.S51800","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S (2014) Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med 7:89\u2013101. https:\/\/doi.org\/10.2147\/IJGM.S51800","journal-title":"Int J Gen Med"},{"key":"3526_CR13","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","volume":"123","author":"M Cazzola","year":"2014","unstructured":"Cazzola M, Kralovics R (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood 123:3714\u20133719. https:\/\/doi.org\/10.1182\/blood-2014-03-530865","journal-title":"Blood"},{"key":"3526_CR14","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/ajh.24592","volume":"91","author":"A Tefferi","year":"2016","unstructured":"Tefferi A (2016) Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 91:1262\u20131271. https:\/\/doi.org\/10.1002\/ajh.24592","journal-title":"Am J Hematol"},{"key":"3526_CR15","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3:e270. https:\/\/doi.org\/10.1371\/journal.pmed.0030270","journal-title":"PLoS Med"},{"key":"3526_CR16","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NCC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Sch\u00f6negger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369:2379\u20132390. https:\/\/doi.org\/10.1056\/NEJMoa1311347","journal-title":"N Engl J Med"},{"key":"3526_CR17","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, du MQ, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369:2391\u20132405. https:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"key":"3526_CR18","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, Colomer D, Pieri L, Pratcorona M, Rotunno G, Sant'Antonio E, Bellini M, Cavalloni C, Mannarelli C, Milanesi C, Boveri E, Ferretti V, Astori C, Rosti V, Cervantes F, Barosi G, Vannucchi AM, Cazzola M, on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators (2014) Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis. Blood 124:1062\u20131069. https:\/\/doi.org\/10.1182\/blood-2014-05-578435","journal-title":"Blood"},{"key":"3526_CR19","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/leu.2014.83","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke C, Belachew AA, Wassie EA, Ketterling RP, Hanson CA, Pardanani A (2014) Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia 28:1568\u20131570. https:\/\/doi.org\/10.1038\/leu.2014.83","journal-title":"Leukemia"},{"key":"3526_CR20","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Tischer A, Wassie EA, Finke CM, Belachew AA, Ketterling RP, Hanson CA, Pardanani AD (2014) The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood 124:2465\u20132466. https:\/\/doi.org\/10.1182\/blood-2014-07-588426","journal-title":"Blood"},{"key":"3526_CR21","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1038\/bcj.2015.90","volume":"5","author":"P Guglielmelli","year":"2015","unstructured":"Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, Pancrazzi A, Vannucchi AM (2015) Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis. Blood Cancer J 5:e360. https:\/\/doi.org\/10.1038\/bcj.2015.90","journal-title":"Blood Cancer J"},{"key":"3526_CR22","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28:1472\u20131477. https:\/\/doi.org\/10.1038\/leu.2014.3","journal-title":"Leukemia"},{"key":"3526_CR23","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NCP, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27:1861\u20131869. https:\/\/doi.org\/10.1038\/leu.2013.119","journal-title":"Leukemia"},{"key":"3526_CR24","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057\u20131069. https:\/\/doi.org\/10.1038\/s41375-018-0077-1","journal-title":"Leukemia"},{"key":"3526_CR25","unstructured":"National Comprehensive Cancer Network (2016) NCCN Guidelines. Myeloproliferative Neoplasms Version 2.2017. https:\/\/www.nccn org\/professionals\/physician_gls\/pdf\/mpn pdf: Accessed November 11, 2016"},{"issue":"Suppl 5","key":"3526_CR26","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, Thiele J, Buske C, Guidelines Committee ESMO (2015) Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v85\u2013v99. https:\/\/doi.org\/10.1093\/annonc\/mdv203","journal-title":"Ann Oncol"},{"key":"3526_CR27","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G (2015) Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN International Working Group. Leukemia 29:2126\u20132133. https:\/\/doi.org\/10.1038\/leu.2015.233","journal-title":"Leukemia"},{"key":"3526_CR28","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","volume":"125","author":"N Kr\u00f6ger","year":"2015","unstructured":"Kr\u00f6ger N, Giorgino T, Scott BL et al (2015) Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood 125:3347\u20133350; quiz 3364. https:\/\/doi.org\/10.1182\/blood-2014-10-608315","journal-title":"Blood"},{"key":"3526_CR29","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.exphem.2007.08.022","volume":"35","author":"N Kr\u00f6ger","year":"2007","unstructured":"Kr\u00f6ger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornh\u00e4user M, Bethge W, Schubert J, de Witte T, Kvasnicka HM, MDS-Subcommittee of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (2007) Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 35:1719\u20131722. https:\/\/doi.org\/10.1016\/j.exphem.2007.08.022","journal-title":"Exp Hematol"},{"key":"3526_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.bbmt.2014.02.019","volume":"20","author":"N Kr\u00f6ger","year":"2014","unstructured":"Kr\u00f6ger N, Zabelina T, Alchalby H, St\u00fcbig T, Wolschke C, Ayuk F, von H\u00fcnerbein N, Kvasnicka HM, Thiele J, Kreipe HH, B\u00fcsche G (2014) Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant 20:812\u2013815. https:\/\/doi.org\/10.1016\/j.bbmt.2014.02.019","journal-title":"Biol Blood Marrow Transplant"},{"key":"3526_CR31","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.bbmt.2014.03.017","volume":"20","author":"V Gupta","year":"2014","unstructured":"Gupta V, Gotlib J, Radich JP, Kr\u00f6ger NM, Rondelli D, Verstovsek S, Deeg HJ (2014) Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis. Biol Blood Marrow Transplant 20:1274\u20131281. https:\/\/doi.org\/10.1016\/j.bbmt.2014.03.017","journal-title":"Biol Blood Marrow Transplant"},{"key":"3526_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.bbmt.2009.10.025","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kr\u00f6ger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M (2010) Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant 16:358\u2013367. https:\/\/doi.org\/10.1016\/j.bbmt.2009.10.025","journal-title":"Biol Blood Marrow Transplant"},{"key":"3526_CR33","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","volume":"89","author":"A Mart\u00ednez-Trillos","year":"2010","unstructured":"Mart\u00ednez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, D\u00edaz-Bey\u00e1 M, Cervantes F (2010) Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 89:1233\u20131237. https:\/\/doi.org\/10.1007\/s00277-010-1019-9","journal-title":"Ann Hematol"},{"key":"3526_CR34","doi-asserted-by":"publisher","unstructured":"Kiladjian JJ (2015) Current therapies and their indications for the Philadelphia-negative myeloproliferative neoplasms. Am Soc Clin Oncol Educ Book e389\u201396. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e389","DOI":"10.14694\/EdBook_AM.2015.35.e389"},{"key":"3526_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366:799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"key":"3526_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"key":"3526_CR37","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","volume":"31","author":"RA Mesa","year":"2013","unstructured":"Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S (2013) Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 31:1285\u20131292. https:\/\/doi.org\/10.1200\/JCO.2012.44.4489","journal-title":"J Clin Oncol"},{"key":"3526_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/bjh.12375","volume":"162","author":"CN Harrison","year":"2013","unstructured":"Harrison CN, Mesa RA, Kiladjian JJ, al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM (2013) Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 162:229\u2013239. https:\/\/doi.org\/10.1111\/bjh.12375","journal-title":"Br J Haematol"},{"key":"3526_CR39","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2016-11-731604","volume":"129","author":"F Cervantes","year":"2017","unstructured":"Cervantes F, Pereira A (2017) Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood 129:832\u2013837. https:\/\/doi.org\/10.1182\/blood-2016-11-731604","journal-title":"Blood"},{"key":"3526_CR40","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3109\/10428194.2014.893310","volume":"55","author":"M Sever","year":"2014","unstructured":"Sever M, Newberry KJ, Verstovsek S (2014) Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory\/resistant to hydroxyurea. Leuk Lymphoma 55:2685\u20132690. https:\/\/doi.org\/10.3109\/10428194.2014.893310","journal-title":"Leuk Lymphoma"},{"key":"3526_CR41","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90:1128\u20131132","journal-title":"Haematologica"},{"key":"3526_CR42","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, Rodeghiero F, d'Amore ESG, Randi ML, Bertozzi I, Marino F, Vannucchi AM, Antonioli E, Carrai V, Gisslinger H, Buxhofer-Ausch V, M\u00fcllauer L, Carobbio A, Gianatti A, Gangat N, Hanson CA, Tefferi A (2011) Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 29:3179\u20133184. https:\/\/doi.org\/10.1200\/JCO.2010.34.5298","journal-title":"J Clin Oncol"},{"key":"3526_CR43","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/leu.2017.297","volume":"32","author":"JC Hern\u00e1ndez-Boluda","year":"2018","unstructured":"Hern\u00e1ndez-Boluda JC, Pereira A, Correa JG, Alvarez-Larr\u00e1n A, Ferrer-Mar\u00edn F, Raya JM, Mart\u00ednez-L\u00f3pez J, P\u00e9rez-Encinas M, Estrada N, Velez P, Fox ML, Garc\u00eda-Guti\u00e9rrez V, Payer A, Kerguelen A, Cuevas B, Dur\u00e1n MA, Ram\u00edrez MJ, G\u00f3mez-Casares MT, Mata-V\u00e1zquez MI, Mora E, Mart\u00ednez-Valverde C, G\u00f3mez M, Cervantes F (2018) Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia 32:553\u2013555. https:\/\/doi.org\/10.1038\/leu.2017.297","journal-title":"Leukemia"},{"key":"3526_CR44","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1182\/blood-2013-09-527903","volume":"123","author":"HL Geyer","year":"2014","unstructured":"Geyer HL, Emanuel RM, Dueck AC et al (2014) Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood 123:1803\u20133810. https:\/\/doi.org\/10.1182\/blood-2013-09-527903","journal-title":"Blood"},{"key":"3526_CR45","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/leu.2014.76","volume":"28","author":"P Guglielmelli","year":"2014","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A, Zoi K, Reiter A, Duncombe A, Fanelli T, Pietra D, Rumi E, Finke C, Gangat N, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NCP, Vannucchi AM, Tefferi A (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28:1804\u20131810. https:\/\/doi.org\/10.1038\/leu.2014.76","journal-title":"Leukemia"},{"key":"3526_CR46","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.24377","volume":"91","author":"G Rotunno","year":"2016","unstructured":"Rotunno G, Pacilli A, Artusi V, Rumi E, Maffioli M, Delaini F, Brogi G, Fanelli T, Pancrazzi A, Pietra D, Bernardis I, Belotti C, Pieri L, Sant'Antonio E, Salmoiraghi S, Cilloni D, Rambaldi A, Passamonti F, Barbui T, Manfredini R, Cazzola M, Tagliafico E, Vannucchi AM, Guglielmelli P (2016) Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM Group. Am J Hematol 91:681\u2013686. https:\/\/doi.org\/10.1002\/ajh.24377","journal-title":"Am J Hematol"},{"key":"3526_CR47","doi-asserted-by":"publisher","unstructured":"Tefferi A, Lasho TL, Hanson CA, Ketterling RP, Gangat N, Pardanani A (2017) Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.15010","DOI":"10.1111\/bjh.15010"},{"key":"3526_CR48","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","volume":"16","author":"R Mesa","year":"2016","unstructured":"Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO (2016) Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN landmark survey. BMC Cancer 16:167. https:\/\/doi.org\/10.1186\/s12885-016-2208-2","journal-title":"BMC Cancer"},{"key":"3526_CR49","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","volume":"96","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA (2017) The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol 96:1653\u20131665. https:\/\/doi.org\/10.1007\/s00277-017-3082-y","journal-title":"Ann Hematol"},{"key":"3526_CR50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, Finke CM, Gangat N, Vaidya R, Begna KH, al-Kali A, Ketterling RP, Hanson CA, Pardanani A (2012) One thousand patients with primary myelofibrosis: the Mayo Clinic experience. Mayo Clin Proc 87:25\u201333. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001","journal-title":"Mayo Clin Proc"},{"key":"3526_CR51","unstructured":"Guglielmelli P, Rotunno G, Pacilli A et al (2016) Differences in clinical and molecular characteristics and outcome in prefibrotic and overt primary myelofibrosis according to 2016 WHO criteria. A study on 639 patients of the AGIMM Group. Blood 128:abstract 943"},{"key":"3526_CR52","doi-asserted-by":"crossref","first-page":"abstract 59","DOI":"10.1182\/blood.V126.23.59.59","volume":"126","author":"CN Harrison","year":"2015","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ et al (2015) Long-term efficacy and safety in COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis: 5-year final study results. Blood 126:abstract 59","journal-title":"Blood"},{"key":"3526_CR53","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10:55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"key":"3526_CR54","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Gupta V, Gotlib JR et al (2016) A pooled overall survival (OS) analysis of 5-year data from the COMFORT-I and COMFORT-II trials of ruxolitinib for the treatment of myelofibrosis (MF). Blood 128:abstract 3110","DOI":"10.1182\/blood.V128.22.3110.3110"},{"key":"3526_CR55","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","volume":"98","author":"S Verstovsek","year":"2013","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865\u20131871. https:\/\/doi.org\/10.3324\/haematol.2013.092155","journal-title":"Haematologica"},{"key":"3526_CR56","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovskaya V, Gupta V, Harrison C, Verstovsek S, on behalf of the COMFORT Investigators (2015) A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 100:1139\u20131145. https:\/\/doi.org\/10.3324\/haematol.2014.119545","journal-title":"Haematologica"},{"key":"3526_CR57","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M (2014) Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 123:1833\u20131835. https:\/\/doi.org\/10.1182\/blood-2013-12-544411","journal-title":"Blood"},{"key":"3526_CR58","doi-asserted-by":"crossref","unstructured":"Mesa RA, Gotlib J, Kantarjian H, Sun W, Verstovsek S (2012) Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms. Poster presented at: 2012 American Society of Hematology Annual Meeting and Exposition; Atlanta, GA","DOI":"10.1182\/blood.V120.21.1727.1727"},{"key":"3526_CR59","doi-asserted-by":"crossref","first-page":"abstract 1128","DOI":"10.1182\/blood.V128.22.1128.1128","volume":"128","author":"F Palandri","year":"2016","unstructured":"Palandri F, Palumbo GA, Bonifacio M et al (2016) Predictors for response to ruxolitinib in real-life: an observational independent study on 408 patients with myelofibrosis. Blood 128:abstract 1128","journal-title":"Blood"},{"key":"3526_CR60","doi-asserted-by":"crossref","first-page":"abstract 7030","DOI":"10.1200\/jco.2013.31.15_suppl.7030","volume":"31","author":"HM Kvasnicka","year":"2013","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos C, Hou K, Cortes J, Kantarjian H, Verstovsek S (2013) Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. J Clin Oncol 31:abstract 7030","journal-title":"J Clin Oncol"},{"key":"3526_CR61","doi-asserted-by":"crossref","first-page":"abstract 4055","DOI":"10.1182\/blood.V122.21.4055.4055","volume":"122","author":"HM Kvasnicka","year":"2013","unstructured":"Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S (2013) Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 122:abstract 4055","journal-title":"Blood"},{"key":"3526_CR62","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","volume":"98","author":"BS Wilkins","year":"2013","unstructured":"Wilkins BS, Radia D, Woodley C, El Farhi S, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitortreatment with ruxolitinib. Haematologica 98:1872\u20131876. https:\/\/doi.org\/10.3324\/haematol.2013.095109","journal-title":"Haematologica"},{"key":"3526_CR63","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian J-J et al (2016) Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 30:1701\u20131707. https:\/\/doi.org\/10.1038\/leu.2016.148","journal-title":"Leukemia"},{"key":"3526_CR64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C (2015) Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST trial. Br J Haematol 170:29\u201339. https:\/\/doi.org\/10.1111\/bjh.13379","journal-title":"Br J Haematol"},{"key":"#cr-split#-3526_CR65.1","unstructured":"Passamonti F, Gupta V, Martino B, et al (2017) Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low\/intermediate-1-, intermediate-2-, and high-risk myelofibrosis (MF) in JUMP, a phase 3B, expanded-access study. EHA annual meeting"},{"key":"#cr-split#-3526_CR65.2","unstructured":"Passamonti F, Gupta V, Martino B, et al (2017) Comparing the safety and efficacy of ruxolitinib (RUX) in patients (PTS) with DIPSS low\/intermediate-1-, intermediate-2-, and high-risk myelofibrosis"},{"key":"#cr-split#-3526_CR65.3","unstructured":"(MF) in JUMP, a phase 3B, expanded-access study. EHA annual meeting; June 22-25, 2017; Madrid, Spain [abstract E1333]"},{"key":"3526_CR66","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"HK Al-Ali","year":"2016","unstructured":"Al-Ali HK, Griesshammer M, le Coutre P et al (2016) Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 101:1065\u20131073. https:\/\/doi.org\/10.3324\/haematol.2016.143677","journal-title":"Haematologica"},{"key":"3526_CR67","doi-asserted-by":"publisher","first-page":"848473","DOI":"10.1155\/2015\/848473","volume":"2015","author":"KL Davis","year":"2015","unstructured":"Davis KL, Cote I, Kaye JA, Mendelson E, Goa H, Perez Ronco J (2015) Real-world assessment of clinical outcomes in patients with lower-risk myelofibrosis receiving treatment with ruxolitinib. Adv Hematol 2015:848473. https:\/\/doi.org\/10.1155\/2015\/848473","journal-title":"Adv Hematol"},{"key":"3526_CR68","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/hon.2429","volume":"36","author":"F Palandri","year":"2017","unstructured":"Palandri F, Tiribelli M, Benevolo G et al (2017) Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: results from an independent study. Hematol Oncol 36:285\u2013290. https:\/\/doi.org\/10.1002\/hon.2429","journal-title":"Hematol Oncol"},{"key":"3526_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/ajh.24572","volume":"92","author":"N Polverelli","year":"2017","unstructured":"Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F (2017) Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. Am J Hematol 92:37\u201341. https:\/\/doi.org\/10.1002\/ajh.24572","journal-title":"Am J Hematol"},{"key":"3526_CR70","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hon.2509","volume":"36","author":"N Polverelli","year":"2018","unstructured":"Polverelli N, Palumbo GA, Binotto G, Abruzzese E, Benevolo G, Bergamaschi M, Tieghi A, Bonifacio M, Breccia M, Catani L, Tiribelli M, D'Adda M, Sgherza N, Isidori A, Cavazzini F, Martino B, Latagliata R, Crugnola M, Heidel F, Bosi C, Ibatici A, Soci F, Penna D, Scaffidi L, Aversa F, Lemoli RM, Vitolo U, Cuneo A, Russo D, Cavo M, Vianelli N, Palandri F (2018) Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: a multicenter study on 446 patients. Hematol Oncol [Epub ahead of print] 36:561\u2013569. https:\/\/doi.org\/10.1002\/hon.2509","journal-title":"Hematol Oncol [Epub ahead of print]"},{"key":"3526_CR71","first-page":"abstract 322","volume":"130","author":"J-J Kiladjian","year":"2017","unstructured":"Kiladjian J-J, Verstovsek S, Griesshammer M et al (2017) Results from the 208-week (4-year) follow-up of RESPONSE trial, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of polycythemia vera (PV). Blood 130:abstract 322","journal-title":"Blood"},{"key":"3526_CR72","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00277-018-3365-y","volume":"97","author":"M Griesshammer","year":"2018","unstructured":"Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F (2018) Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Ann Hematol 97:1591\u20131600. https:\/\/doi.org\/10.1007\/s00277-018-3365-y","journal-title":"Ann Hematol"},{"key":"3526_CR73","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjh.12459","volume":"162","author":"JC Ianotto","year":"2013","unstructured":"Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ (2013) Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French Cooperative Groups. Br J Haematol 162:783\u2013791. https:\/\/doi.org\/10.1111\/bjh.12459","journal-title":"Br J Haematol"},{"key":"3526_CR74","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","volume":"97","author":"K Gowin","year":"2012","unstructured":"Gowin K, Thapaliya P, Samuelson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R (2012) Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 97:1570\u20131573. https:\/\/doi.org\/10.3324\/haematol.2011.061390","journal-title":"Haematologica"},{"key":"3526_CR75","doi-asserted-by":"crossref","first-page":"abstract 944","DOI":"10.1182\/blood.V128.22.944.944","volume":"128","author":"RT Silver","year":"2016","unstructured":"Silver RT, Barel A, Lascu E, Ritchie EK, Roboz GJ, Christos P, Orazi A, Hassane DC, Tam W, Cross NCP (2016) The effect of initial molecular profile on response to recombinant interferon alpha (rIFN\u03b1) treatment in early myelofibrosis. Blood 128:abstract 944","journal-title":"Blood"},{"key":"3526_CR76","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00277-016-2631-0","volume":"95","author":"C O'Neill","year":"2016","unstructured":"O'Neill C, Siddiqi I, Brynes RK, Vergara-Lluri M, Moschiano E, O'Connell C (2016) Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy. Ann Hematol 95:733\u2013738. https:\/\/doi.org\/10.1007\/s00277-016-2631-0","journal-title":"Ann Hematol"},{"key":"3526_CR77","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3324\/haematol.2014.115840","volume":"100","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H, For the COMFORT-I investigators (2015) Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100:479\u2013488. https:\/\/doi.org\/10.3324\/haematol.2014.115840","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3526-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3526-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T17:07:11Z","timestamp":1605287231000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3526-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,20]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3526-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,20]]},"assertion":[{"value":"5 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Francesca Palandri has received an honorarium from Novartis; Elena Sabattini has received honoraria from Novartis for educational events. Margherita Maffioli has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}